Compare Stocks → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APVONASDAQ:CALANASDAQ:CINGNASDAQ:VYNE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$4.69+15.5%$6.08$3.81▼$92.62$2.02M4.93102,444 shs293,949 shsCALACalithera Biosciences$0.02$0.03$0.01▼$0.50$120K-0.171,601 shs163 shsCINGCingulate$1.10+0.9%$1.76$1.00▼$23.80$1.02M-0.92371,310 shs74,514 shsVYNEVYNE Therapeutics$3.07+3.7%$2.16$1.67▼$8.73$41.73M1.18137,814 shs294,678 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+15.52%+4.69%-28.41%-41.11%-94.72%CALACalithera Biosciences+22.75%-2.00%-2.19%-18.17%-55.36%CINGCingulate+0.92%+1.85%+0.92%-85.62%-94.66%VYNEVYNE Therapeutics+3.72%+31.76%+29.54%+31.76%+18.30%Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics0.3199 of 5 stars0.02.00.00.03.00.01.3CALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACINGCingulate3.9308 of 5 stars3.25.00.00.02.94.21.3VYNEVYNE Therapeutics3.8239 of 5 stars3.55.00.00.03.91.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics3.00BuyN/AN/ACALACalithera BiosciencesN/AN/AN/AN/ACINGCingulate2.33Hold$8.00627.27% UpsideVYNEVYNE Therapeutics3.00Buy$7.38140.23% UpsideCurrent Analyst RatingsLatest CALA, VYNE, CING, and APVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/29/2024VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.751/5/2024CINGCingulateHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M0.65N/AN/A$28.58 per share0.16CALACalithera Biosciences$9.75M0.01N/AN/A($0.40) per share-0.06CINGCingulateN/AN/AN/AN/A$6.87 per shareN/AVYNEVYNE Therapeutics$420K103.06N/AN/A$6.36 per share0.48Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$17.41MN/A0.00N/AN/AN/A-112.27%-64.39%5/9/2024 (Estimated)CALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/A3/29/2024 (Estimated)CINGCingulate-$17.68M-$32.60N/AN/AN/AN/A-1,235.83%-285.93%3/29/2024 (Estimated)VYNEVYNE Therapeutics-$28.45M-$7.04N/AN/AN/A-6,710.38%-77.46%-62.93%5/9/2024 (Estimated)Latest CALA, VYNE, CING, and APVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023VYNEVYNE Therapeutics-$0.50-$0.20+$0.30-$0.20$0.15 million$0.08 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A2.642.64CALACalithera BiosciencesN/AN/AN/ACINGCingulateN/A0.510.51VYNEVYNE TherapeuticsN/A12.7312.73OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%CALACalithera BiosciencesN/ACINGCingulate41.31%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics1.90%CALACalithera Biosciences6.60%CINGCingulate38.43%VYNEVYNE Therapeutics1.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics40430,000420,000Not OptionableCALACalithera Biosciences84.87 million4.55 millionNot OptionableCINGCingulate15937,000577,000Not OptionableVYNEVYNE Therapeutics1014.10 million13.85 millionNot OptionableCALA, VYNE, CING, and APVO HeadlinesSourceHeadlineShort Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Drops By 63.4%americanbankingnews.com - March 29 at 3:40 AMAcne Treatment Market Poised for Substantial Growth, Anticipated to Reach USD 16.2 Billion by 2032pharmiweb.com - March 28 at 12:46 PMVYNE Therapeutics (NASDAQ:VYNE) Stock Price Up 3.9%americanbankingnews.com - March 23 at 1:48 AMVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conferencefinance.yahoo.com - March 19 at 9:08 AMVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conferenceglobenewswire.com - March 19 at 8:00 AMHere's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Nowzacks.com - March 13 at 10:56 AMWhat Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stockzacks.com - March 8 at 1:01 PMWall Street Breakfast Podcast: NYCB Gets $1B Investment Boostseekingalpha.com - March 7 at 8:21 AMVYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - March 3 at 8:59 AMBuy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developmentsmarkets.businessinsider.com - February 29 at 7:00 PMVYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Updatefinanznachrichten.de - February 29 at 10:04 AMVYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Updateglobenewswire.com - February 29 at 8:00 AMVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposiumfinance.yahoo.com - February 27 at 8:06 AMVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposiumglobenewswire.com - February 27 at 8:00 AMVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferencefinance.yahoo.com - February 21 at 8:16 AMVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 21 at 8:00 AMFavourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stockfinance.yahoo.com - February 2 at 7:18 AMBuy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial Resultsmarkets.businessinsider.com - January 10 at 4:27 PMPrurigo Nodularis Treatment Market Forecasts Surpassing US$ 930.9 Million by 2033-FMI Studyfmiblog.com - January 4 at 12:32 AMVYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directorsfinance.yahoo.com - January 3 at 9:29 AMInvesting in VYNE Therapeutics Inc [VYNE]: What You Must Knowknoxdaily.com - January 1 at 10:15 AMVYNE Therapeutics says director Lepore buys 13K shares in comsn.com - November 20 at 3:25 PMCormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics Incfinance.yahoo.com - November 14 at 5:53 PMVYNE Therapeutics files to sell 36.27M shares for holdersmsn.com - November 13 at 5:35 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesPayPal Appears to Have Bottomed, is it Time to Buy?March 22, 2024 9:11 AMView PayPal Appears to Have Bottomed, is it Time to Buy?5 Dividend Kings Stocks to Load Up on NowMarch 27, 2024 7:45 AMView 5 Dividend Kings Stocks to Load Up on NowChipotle Stock Shoots Higher, Announcing 50 for 1 Stock SplitMarch 20, 2024 10:26 AMView Chipotle Stock Shoots Higher, Announcing 50 for 1 Stock SplitShould You Buy Boeing Stock After CEO Resignation Announcement?March 25, 2024 11:10 AMView Should You Buy Boeing Stock After CEO Resignation Announcement?Cars.com and Carvana Stock Facing Weaker Consumer SentimentFebruary 28, 2024 8:45 AMView Cars.com and Carvana Stock Facing Weaker Consumer SentimentAll Headlines Company DescriptionsAptevo TherapeuticsNASDAQ:APVOAptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Calithera BiosciencesNASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.CingulateNASDAQ:CINGCingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.VYNE TherapeuticsNASDAQ:VYNEVYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.